Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD001 Plus Octreotide Depot in Low Grade Neuroendocrine Carcinoma
NCT00113360Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2005
- Primary completion
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in neuroendocrine carcinoma (NEC) and islet cell carcinoma (ICC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Progression-Free Survival. Started Jan 2005; status: completed.
02
Drugs
everolimus
03
Conditions
neuroendocrine carcinoma (NEC)islet cell carcinoma (ICC)
Beyond the preview
Go deeper on NCT00113360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00113360.